Shots:
- The acquisition will bolster Verily’s clinical trial system and Baseline platform to improve the efficiency, costs in clinical trials & speed up it at research sites globally. It also collects patient data for site-based, hybrid, and decentralized clinical studies
- SignalPath’s platform leverages modern software architecture with a cloud-based platform to reduces fragmentation & advance the management of clinical trials portfolio
- SignalPath employees will join Verily’s clinical research business to increase its geographic footmark in North Carolina while maintaining its physical presence in Raleigh
Click here to read full press release/ article | Ref: Businesswire | Image: Stat News
The post Verily Acquires SignalPath to Expand its Clinical Research Capabilities first appeared on PharmaShots.
